Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

44 results about "Maintenance therapy" patented technology

Maintenance therapy is a medical therapy that is designed to help a primary treatment succeed. For example, maintenance chemotherapy may be given to people who have a cancer in remission in an attempt to prevent a relapse. This form of treatment is also a common approach for the management of many incurable, chronic diseases such as periodontal disease, Crohn's disease or ulcerative colitis.

Method of using adapalene in acne maintenance therapy

InactiveUS20060128808A1Prevent acne recurrenceControl acne recurrenceBiocideAnimal repellantsMaintenance therapyAdapalene
The present invention provides for a method of using adapalene for the maintenance theray of acne vulgaris to prevent acne recurrence or reduce the severity of the acne recurrence.
Owner:GALDERMA RES & DEV SNC

Composition for treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant of anti-anxiety drug

The present invention encompasses methods of treating patients for tobacco addiction and nicotine addiction, for palliating the effects of nicotine withdrawal, for providing or facilitating the effects of smoking cessation therapies and as long-term smoking cessation maintenance therapy. The invention also includes related pharmaceutical compositions comprising nicotine receptor antagonists and either an anti-depressant or an anti-anxiety drug. Specific combinations of drugs (mecamylamine HCl and bupropion HCl) as well as mecamylamine in combination with certain drug classes (e.g., anti-anxiety drugs and anti-depressants) comprise the pharmaceutical compositions disclosed. These compositions are also contemplated for use in the treatment of cocaine addiction and the treatment of alcohol dependence.
Owner:CARY PHARMA

Medicine supplying device of medicine maintenance therapy equipment for drug addicts under control to give up drug habits

PendingCN110269803AConvenient automatic medicine supplyQuick and automatic medicine supplyDrug and medicationsOral administration deviceMaintenance therapyTherapeutic Devices
The invention relates to a medicine supplying device of medicine maintenance therapy equipment for drug addicts under control to give up drug habits. A first driving motor of a medicine drinking cup providing assembly can drive cup separating wheels to rotate through a first transmission mechanism; the cup separating wheels are used for supporting a medicine drinking cup pile to be provided; during rotating, the cup separating wheels are separated from a medicine drinking cup at the bottommost layer and are used for bearing the medicine drinking cup at an upper layer, so that the medicine drinking cup at the bottommost layer is driven to fall from a cup providing hole; a second driving motor of a transmission assembly is used for driving a manipulator to move through a second transmission mechanism; after the medicine drinking cup falling down from the medicine providing hole is taken by the manipulator at a cup receiving position, the manipulator can move to a medicine drinking position and transmit the medicine drinking cup to the medicine drinking position; and a liquid medicine peristalsis pump can inject liquid medicines stored in a liquid medicine storage container to the medicine drinking cup transmitted to the medicine drinking position to allow the drug addicts under control to give up drug habits to drink. Through the adoption of the medicine supplying device disclosed by the invention, the medicine maintenance therapy equipment for drug addicts under control to give up drug habits can conveniently, quickly and automatically feed medicines for the drug addicts under control to give up drug habits.
Owner:内蒙古银安科技开发有限责任公司

Metoprolol sustained-release dropping pill and preparation method thereof

InactiveCN101269032ASmall blocking effectNo endogenous sympathomimetic activityOrganic active ingredientsPharmaceutical delivery mechanismMaintenance therapyHyperthyroidism/thyrotoxicosis
The invention relates to a fast-effect slow-release sustained-release metoprolol dropping pill used for treating hypertension, angina, the maintenance therapy after myocardial infarction and hyperthyroidism and the preparation method thereof, and aims to supplement the deficiency of the prior art and provide a sustained-release metoprolol dropping pill. The sustained-release metoprolol dropping pill is added with a hydrophobic framework capable of sustaining drug release and tween-80 playing the role of solubilization on the basis of the existing dropping pill technology, thereby overcoming the defects in the prior art effectively and having the advantages of even drug distribution, full release, long release time, reduced frequency of drug taking for patients and high bioavailability simultaneously.
Owner:北京博智绿洲医药科技有限公司

Dosing regimens and methods for treating or preventing myelodysplastic syndrome

InactiveUS20120309846A1BiocideKetone active ingredientsMaintenance therapyMenatetrenone
The invention encompasses dosing regimens in which a subject is administered menatetrenone over a period of time to establish initial therapeutic baseline blood concentration of the menatetrenone followed by a maintenance therapy to maintain therapeutic blood concentrations. In other embodiments, the invention encompasses methods of treating myelodysplastic syndrome in a subject in need thereof comprising administering to a subject a therapeutically effective dosing regimen of menatetrenone.
Owner:NBI PHARMA INC

Treatment of multiple sclerosis by alemtuzumab induction followed by laquinimod therapy

This invention provides a method of treating a subject afflicted with multiple sclerosis (MS) or presenting clinically isolated syndrome (CIS) which comprises a) administering to the subject an amount of an anti-CD52 antibody, followed by b) periodically administering to the subject an amount of laquinimod. This invention also provides packages comprising pharmaceutical compositions of laquinimod or an anti-CD52 antibody for treating such a subject wherein laquinimod is to be administered as a maintenance therapy in such a subject who has received an anti-CD52 antibody induction therapy.
Owner:TEVA PHARMA IND LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products